HM
HealthCor Management Portfolio holdings
AUM
$109M
This Quarter Return
-2.84%
1 Year Return
+11.46%
3 Year Return
+50.01%
5 Year Return
+144.68%
10 Year Return
–
AUM
$1.45B
AUM Growth
+$1.45B
(-20%)
Cap. Flow
-$343M
Cap. Flow
% of AUM
-23.71%
Top 10 Holdings %
Top 10 Hldgs %
42.51%
Holding
79
New
11
Increased
20
Reduced
21
Closed
14
Top Buys
| 1 |
BioMarin Pharmaceuticals
BMRN
|
$47M |
| 2 |
Cytokinetics
CYTK
|
$38.3M |
| 3 |
Becton Dickinson
BDX
|
$37.6M |
| 4 |
Teleflex
TFX
|
$35.2M |
| 5 |
Abbott
ABT
|
$33.4M |
Top Sells
| 1 |
Medtronic
MDT
|
$158M |
| 2 |
Bristol-Myers Squibb
BMY
|
$93.1M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
$52.9M |
| 4 |
Johnson & Johnson
JNJ
|
$47.9M |
| 5 |
Tenet Healthcare
THC
|
$42.8M |
Sector Composition
| 1 | Healthcare | 95.52% |
| 2 | Consumer Discretionary | 1.65% |
| 3 | Financials | 0.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biogen
BIIB
$19.4B
| $84.6M | 5.64% | 401,660 -51,740 | -11% | -$10.9M |
|
2
Boston Scientific
BSX
$156B
| $82M | 5.47% | 1,850,450 +586,780 | +46% | +$26M |
|
|
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $74.7M | 4.98% | 710,110 -122,160 | -15% | -$12.9M |
|
|
4
BioMarin Pharmaceuticals
BMRN
$11.2B
| $59.3M | 3.96% | 769,016 +609,696 | +383% | +$47M |
|
5
Natera
NTRA
$23.1B
| $59M | 3.93% | 1,449,536 +696,616 | +93% | +$28.3M |
|
|
6
Abbott
ABT
$231B
| $57.4M | 3.83% | 484,740 +282,030 | +139% | +$33.4M |
|
7
Centene
CNC
$14.3B
| $53.4M | 3.56% | 634,610 -115,660 | -15% | -$9.74M |
|
8
Cencora
COR
$56.5B
| $51.2M | 3.42% | 330,910 -190,010 | -36% | -$29.4M |
|
9
Humana
HUM
$36.5B
| $47.5M | 3.17% | 109,040 +54,400 | +100% | +$23.7M |
|
10
Cooper Companies
COO
$13.4B
| $45.3M | 3.02% | 108,590 +28,460 | +36% | +$11.9M |
|
11
Envista
NVST
$3.52B
| $44.5M | 2.97% | 914,490 -728,190 | -44% | -$35.5M |
|
|
12
Cytokinetics
CYTK
$4.23B
| $41.8M | 2.79% | 1,135,110 +1,040,990 | +1,106% | +$38.3M |
|
13
AbbVie
ABBV
$372B
| $41.2M | 2.75% | 254,160 +129,010 | +103% | +$20.9M |
|
14
LivaNova
LIVN
$3.08B
| $41.1M | 2.74% | 502,350 +71,750 | +17% | +$5.87M |
|
15
Incyte
INCY
$16.5B
| $39.7M | 2.65% | 500,400 +392,350 | +363% | +$31.2M |
|
|
16
Bristol-Myers Squibb
BMY
$96B
| $38.7M | 2.58% | 530,160 -1,274,390 | -71% | -$93.1M |
|
|
17
Becton Dickinson
BDX
$55.3B
| $37.6M | 2.51% | +141,460 | New | +$37.6M |
|
18
UnitedHealth
UNH
$281B
| $37M | 2.47% | 72,580 +43,580 | +150% | +$22.2M |
|
19
Elevance Health
ELV
$71.8B
| $36M | 2.4% | 73,350 -28,210 | -28% | -$13.9M |
|
|
20
Teleflex
TFX
$5.59B
| $35.2M | 2.35% | +99,150 | New | +$35.2M |
|
21
Universal Health Services
UHS
$11.6B
| $33.1M | 2.21% | 228,410 -57,210 | -20% | -$8.29M |
|
22
McKesson
MCK
$85.4B
| $29.3M | 1.96% | 95,800 +31,730 | +50% | +$9.71M |
|
23
CVS Health
CVS
$92.8B
| $29M | 1.94% | +286,600 | New | +$29M |
|
24
Danaher
DHR
$147B
| $28.6M | 1.91% | 97,490 -53,100 | -35% | -$15.6M |
|
|
RVNC
25
DELISTED
Revance Therapeutics, Inc.
RVNC
| $27.8M | 1.85% | 1,423,425 -26,410 | -2% | -$515K |
|